Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5375 Target Snapshot

Hepatitis C virus NS5B RNA-dependent RNA polymerase · SINGLE PROTEIN · Hepatitis C virus

60Compounds
10Assays
2Approved Drugs
59.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q8JXU8. Use UniProt Q8JXU8 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8JXU8 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Hepatitis C virus NS5B RNA-dependent RNA polymerase as ChEMBL target CHEMBL5375, mapped to UniProt Q8JXU8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Hepatitis C virus NS5B RNA-dependent RNA polymerase
SINGLE PROTEIN · Hepatitis C virus
As of 2026-09-13
ChEMBL target ID
CHEMBL5375
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q8JXU8
RNA-directed RNA polymerase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Hepatitis C virus NS5B RNA-dependent RNA polymerase is the right protein anchor across sources, using UniProt Q8JXU8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRNA-directed RNA polymerase
UniProt AccessionQ8JXU8
Component TypeProtein
Sequence Length231 aa

RNA-directed RNA polymerase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Hepatitis C virus NS5B RNA-dependent RNA polymerase, mapped to UniProt Q8JXU8. ChEMBL maps the protein component as RNA-directed RNA polymerase. Sequence length is 231 aa.

Mapped IDQ8JXU8
Review nameHepatitis C virus NS5B RNA-dependent RNA polymerase
OrganismHepatitis C virus
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC5016.0
KI1.0
EC5042.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3545363 10.28 Ki 0.053 Approved
CHEMBL230744 8.52 IC50 3.0 Preclinical
CHEMBL3039514 8.52 EC50 3.0 Approved
CHEMBL509746 8.3 IC50 5.0 Preclinical
CHEMBL5937877 8.3 EC50 5.0 Preclinical
CHEMBL5889149 8.22 EC50 6.0 Preclinical
CHEMBL490672 8.15 IC50 7.0 Clinical
CHEMBL489295 7.92 IC50 12.0 Preclinical
CHEMBL490671 7.8 IC50 16.0 Preclinical
CHEMBL5783938 7.47 EC50 34.0 Preclinical
Distribution

pChEMBL Value Distribution

3
5.0
11
5.5
11
6.0
7
6.5
7
7.0
2
7.5
5
8.0
3
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GLECAPREVIR
CHEMBL3545363
Approved 2017
ELBASVIR
CHEMBL3039514
Approved 2016
Assay Landscape

Assay Landscape

10
Total Assays
56
Tested Compounds
1
Assay Types
Binding — 10 assays, 56 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 9 18 6.7
assay format 1 38 6.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine